U.S. Banks Stock News

NasdaqGS:NBIS
NasdaqGS:NBISSoftware

US Stock Market Today: S&P 500 Futures Edge Higher On Mixed Factory Data And Yields

The Morning Bull - US Market Morning Update Tuesday, Mar, 17 2026 E-mini S&P 500 futures are pointing higher this morning, up about 0.4%, as investors juggle mixed US factory data and rising pressure from the bond market. The NY Empire State Manufacturing Index sits at -0.2 in March, which means activity in New York factories has essentially stalled, a concern for jobs and overtime pay in industrial regions. At the same time, the 10 year US Treasury yield is holding near 4.24%, keeping...
NasdaqGM:CRMD
NasdaqGM:CRMDPharmaceuticals

Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Long Term Gains

Stock performance context for CorMedix Without a specific news catalyst driving fresh headlines, CorMedix (CRMD) continues to draw attention as investors weigh its recent share performance in relation to its role in developing therapies for life threatening conditions. The stock last closed at US$6.54, with returns showing mixed momentum. It recorded a 1.4% gain over the past day, alongside a slight decline over the past week. See our latest analysis for CorMedix. Recent trading tells a mixed...
NasdaqGS:SLAB
NasdaqGS:SLABSemiconductor

Did Silicon Labs’ In‑Tire Sensor Deal With BANF Just Shift Silicon Laboratories’ (SLAB) Investment Narrative?

Earlier this month, BANF announced a collaboration with Silicon Labs to integrate the ultra‑low‑power BG22 Bluetooth LE SoC and Secure Vault security into BANF’s new in‑tire, battery‑free sensor platform for autonomous and connected vehicles. By digitizing real‑time tire conditions with on‑tire data processing and wireless power transfer, the partnership turns tires into high‑value data sources for safety, fleet management, and future predictive services. We’ll now examine how embedding...
NasdaqGS:SVCO
NasdaqGS:SVCOSoftware

A Look At Silvaco Group (SVCO) Valuation After Earnings Beat And AI Segment Growth

Silvaco Group (SVCO) surprised the market with quarterly results that came in ahead of expectations, along with revenue guidance above earlier forecasts and cost cuts tracking better than management initially outlined. See our latest analysis for Silvaco Group. Silvaco Group’s recent earnings beat and upbeat guidance have been met with sharp share price momentum, with a 7 day share price return of 53.5% and a year to date share price return of 22%, even though the 1 year total shareholder...
NasdaqGS:SAFT
NasdaqGS:SAFTInsurance

Assessing Safety Insurance Group (SAFT) Valuation After Improved Combined Ratio And Dividend Strength

Safety Insurance Group (SAFT) is in focus after reporting an improved combined ratio of 99% in 2024, a well covered dividend, and a 4.2% yield on its investment portfolio. See our latest analysis for Safety Insurance Group. The share price sits at $73.53 after a 1 day share price return of 0.40% and a 7 day share price return of 1.21%. However, the 30 day share price return of 7.31% and year to date share price return of 2.88% point to fading short term momentum. The 3 year total shareholder...
NYSE:TSQ
NYSE:TSQMedia

Townsquare Media (TSQ) Returns To Loss In Q4 EPS Challenging Profit Recovery Narrative

Townsquare Media (TSQ) FY 2025 Earnings Snapshot Townsquare Media (TSQ) has wrapped up FY 2025 with Q4 revenue of US$106.5 million and a basic EPS loss of US$0.32, while trailing twelve month figures show revenue at US$427.4 million and a basic EPS loss of US$0.71. Over recent quarters the company has seen revenue move from US$117.8 million in Q4 2024 to US$106.5 million in Q4 2025, with EPS shifting from a profit of US$1.59 to a loss of US$0.32. This sets up a story where revenue is...
NasdaqGS:CYTK
NasdaqGS:CYTKBiotechs

Cytokinetics MYQORZO Data Sheds Light On oHCM Outlook And Valuation

Cytokinetics (NasdaqGS:CYTK) presented new clinical data on MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy at a major cardiology conference. The updates covered exercise capacity outcomes, effectiveness across patients with and without hypertension, and safety during treatment interruption and restart. The new analyses expand the clinical profile of MYQORZO, a recently approved oHCM therapy, and add detail on how the drug performs in real treatment scenarios. Cytokinetics...
NYSE:SFBS
NYSE:SFBSBanks

Is ServisFirst Bancshares (SFBS) Offering A Chance After Recent Share Price Weakness

Wondering whether ServisFirst Bancshares is attractively priced at its current level? This article focuses squarely on what the recent share performance might be telling you about value. The stock last closed at US$73.73, with returns of 2.7% year to date, a 14.4% decline over the past month, and a 9.7% decline over the past year, while still showing a 35.2% gain over three years and 31.1% over five years. These mixed returns have kept ServisFirst Bancshares on the radar for investors who...
NasdaqGS:UBSI
NasdaqGS:UBSIBanks

Is United Bankshares (UBSI) Still Sensibly Priced After The Recent Share Price Pullback?

Wondering if United Bankshares at around US$39.38 is still a fair deal or starting to look stretched? This article breaks down what the current share price might be implying about value. The stock’s returns range from a 1.4% decline over the last 7 days and a 10.7% decline over the last 30 days, to gains of 2.6% year to date, 17.5% over 1 year, 25.7% over 3 years and 25.2% over 5 years. These figures can mean very different things depending on how you think about risk and timing. Recent...
NasdaqGM:TLS
NasdaqGM:TLSSoftware

Telos (TLS) Q4 Loss Rebound Challenges Bullish Margin Improvement Narratives

Telos (TLS) just closed out FY 2025 with Q4 revenue of US$46.8 million and a basic EPS loss of US$0.22, capping a year in which trailing twelve month revenue came in at US$164.8 million and EPS on the same basis was a loss of US$0.50. Over recent quarters the company has seen revenue move from US$26.4 million in Q4 2024 to US$30.6 million in Q1 2025, US$36.0 million in Q2, US$51.4 million in Q3, and US$46.8 million in Q4, while quarterly basic EPS losses ranged between US$0.03 and US$0.22...
NasdaqGS:LFCR
NasdaqGS:LFCRLife Sciences

Lifecore Biomedical (LFCR) Q4 Loss Narrows To US$2 Million Reinforcing Bullish Margin Narratives

Lifecore Biomedical (LFCR) just posted its FY 2025 fourth quarter numbers, with revenue of US$36.4 million and a basic EPS loss of US$0.06. This sets the tone for a year where the trailing twelve months show revenue at about US$129.5 million and a basic EPS loss of US$0.92. Over recent quarters, revenue has moved from US$24.7 million in Q1 FY 2025 to US$31.1 million in Q3 and then US$36.4 million in Q4. Quarterly basic EPS losses ranged from US$0.53 in Q1 to US$0.29 in Q3 and US$0.06 in Q4,...
NYSE:ZEPP
NYSE:ZEPPElectronic

Zepp Health (ZEPP) Q4 Loss Narrows To US$0.69 EPS Challenging Bearish Profitability Narratives

Zepp Health (ZEPP) has wrapped up FY 2025 with fourth quarter revenue of US$85.2 million and a basic EPS loss of US$0.69, setting the tone for how you might read the full year at the current share price of US$16.22. The company has seen quarterly revenue move from US$59.5 million in Q4 2024 to US$85.2 million in Q4 2025, while basic EPS over that stretch has shifted from a loss of US$2.29 to a loss of US$0.69. This puts the focus squarely on how sustainably margins can tighten those losses...
NasdaqGS:SAIC
NasdaqGS:SAICProfessional Services

SAIC (SAIC) Earnings Growth And 5% Margin Reinforce Bullish Profitability Narratives

Science Applications International (SAIC) has just posted fresh FY 2026 numbers, with third quarter revenue of US$1,866 million and basic EPS of US$1.70, alongside trailing 12 month revenue of US$7.4 billion and EPS of US$7.86. Over recent quarters the company has seen revenue range from US$1,769 million to US$1,877 million and quarterly EPS move between US$1.43 and US$2.72. This gives investors a clearer view of how the current run rate feeds into those trailing figures. With trailing net...
NasdaqGS:DLTR
NasdaqGS:DLTRConsumer Retailing

Dollar Tree (DLTR) Margin Compression To 5.9% Tests Bullish Earnings Narratives

Dollar Tree (DLTR) has just posted its latest FY 2026 numbers, with Q3 revenue of US$4.8b and basic EPS of US$1.20 setting the tone for the year to date. The company has seen quarterly revenue move from US$4.1b in Q2 FY 2025 to US$4.6b in Q1 FY 2026 and US$4.8b in Q3 FY 2026, while basic EPS has ranged from US$0.66 to US$1.47 over the same stretch, giving you a clear read on how sales and earnings are tracking into the back half of the year. With trailing 12 month net income described as high...
NasdaqGS:VFS
NasdaqGS:VFSAuto

VinFast Auto (NasdaqGS:VFS) Loss Deepens In Q3 EPS And Reinforces Bearish Profitability Concerns

VinFast Auto (NasdaqGS:VFS) has just posted another loss making quarter, with Q3 FY 2025 revenue of about ₫18.1 trillion and basic EPS of a loss of ₫10,238.74, set against a trailing twelve month revenue base of roughly ₫67.5 trillion and a cumulative loss of about ₫92.5 trillion. Over recent periods the company has seen quarterly revenue move from about ₫8.7 trillion in Q2 FY 2024 to ₫12.3 trillion in Q3 FY 2024, ₫16.3 trillion in Q1 FY 2025 and now ₫18.1 trillion in Q3 FY 2025, while...
NYSE:WBI
NYSE:WBIEnergy Services

WaterBridge Infrastructure (WBI) Quarterly Loss Despite US$123.25m Revenue Tests Bullish Re Rating Hopes

Latest FY 2025 Earnings Snapshot WaterBridge Infrastructure (WBI) just posted its FY 2025 numbers with third quarter revenue of US$123.25 million and a basic EPS loss of US$0.02, while net income excluding extra items was a loss of US$0.67 million. The company has seen revenue move from US$89.80 million in the third quarter of 2024 to US$123.25 million in the same period of 2025. The trailing twelve month revenue figure in the dataset stands at US$733.30 million with a net loss of US$91.25...
NasdaqGS:APLS
NasdaqGS:APLSBiotechs

Does Apellis Pharmaceuticals' (APLS) New Board Member Reveal a Deeper R&D Commercialization Strategy Shift?

Apellis Pharmaceuticals recently added Mikael Dolsten, M.D., Ph.D., former chief scientific officer of Pfizer, to its board of directors, bringing decades of high-level research and development leadership across major global drug makers. This appointment, alongside growing analyst interest in Apellis’s key products Empaveli and Syfovre, underscores how external experts view the company’s pipeline and commercial portfolio as increasingly relevant in rare kidney disease and eye care...
NYSE:KFY
NYSE:KFYProfessional Services

How Investors Are Reacting To Korn Ferry (KFY) Earnings Beat, Higher Dividend And Q4 Outlook

Korn Ferry recently reported third-quarter fiscal 2026 results showing year-over-year growth in revenue to US$725.04 million and higher net income of US$65.27 million, alongside guidance for fourth-quarter fee revenue of US$730 million to US$750 million and diluted EPS of US$1.34 to US$1.40. The company also approved a 15% increase in its quarterly dividend to US$0.55 per share, signaling confidence in its cash generation while adding former Deloitte U.S. COO Pete Shimer to its board,...
NYSE:GPK
NYSE:GPKPackaging

Is It Time To Reconsider Graphic Packaging Holding (GPK) After Recent Share Price Strength?

To help you decide whether Graphic Packaging Holding might offer value at today’s price, this article focuses squarely on what the current share price implies about the company. Recently, the stock has been weak, with returns of 9.7% over 7 days, 21.7% over 30 days, 35.8% year to date, and 61.8% over the last year, which may indicate that expectations and risk perceptions have shifted. These moves come as the company continues to attract attention in packaging, where investors often weigh...
NasdaqGS:FBNC
NasdaqGS:FBNCBanks

First Bancorp CEO Retirement Puts Focus On Leadership Continuity And Dividends

First Bancorp (NasdaqGS:FBNC) announced the retirement of Michael G. Mayer from his roles as President and CEO of First Bank. Mayer is stepping back from day to day management but will continue to serve on the company’s Board of Directors. The change marks a leadership transition at the top of First Bank’s operating structure. First Bancorp, the holding company for First Bank, operates as a regional banking platform, offering lending, deposit, and related financial services. Leadership...
NYSE:VIA
NYSE:VIASoftware

Via Transportation (VIA) Valuation Check After Recent Share Price Weakness

Recent price performance and business snapshot Via Transportation (VIA) has drawn attention after its share price declined about 7% over the past week and roughly 43% over the past 3 months, putting recent trading under closer investor review. The New York based transit software company reports annual revenue of US$434.3 million and a net loss of US$96.4 million. Its services span planning tools, operations software, and tech enabled transit solutions for public and private clients. See our...
NasdaqGS:CERT
NasdaqGS:CERTHealthcare Services

Assessing Certara (CERT) Valuation After FDA PBPK Milestone And New Biosimulation Software Launches

Certara (CERT) is back on investors’ radar after closing 2025 with revenue of US$418.8m, a small net loss, and fresh FDA validation of its biosimulation platform through PBPK modeling used in the asciminib NDA. See our latest analysis for Certara. Despite FDA validation for its PBPK work and new software launches, Certara’s share price has been under pressure, with a 90 day share price return of 23.91% and a 1 year total shareholder return of 39.10%. This may indicate fading momentum after...
NasdaqGS:WLTH
NasdaqGS:WLTHCapital Markets

Wealthfront (WLTH) Valuation Check As Mixed Recent Returns Temper Earlier Share Price Strength

Event context for Wealthfront stock Wealthfront (WLTH) has drawn fresh attention after recent trading left the share price at US$7.86, with short term returns mixed and a value score of 4 prompting closer inspection from investors. See our latest analysis for Wealthfront. That recent 1 day share price return of 0.25% and 7 day share price return of 7.42% sit against a 90 day share price return of 43.66% and year to date share price return of 40.54%, suggesting momentum has been fading even...
NasdaqGS:FIZZ
NasdaqGS:FIZZBeverage

What National Beverage (FIZZ)'s Resilient EPS and Rising Shipments Mean for Shareholders

National Beverage Corp. recently reported past third-quarter results showing sales of US$264.59 million and net income of US$41.21 million, with basic and diluted earnings per share of US$0.44, slightly higher than a year earlier despite modestly lower revenue. The company also cited a 7% increase in January shipments and encouraging early fourth-quarter volume trends, suggesting that new product introductions and its decision not to fully pass through tariffs to consumers are helping...